Indication
In combination with mycophenolate mofetil (MMF) for the treatment of adult patients with active Class III or IV, with or without concomitant Class V, lupus nephritis (LN).
Medicine details
- Medicine name:
- obinutuzumab (Gazyvaro)
- SMC ID:
- SMC2903
- Pharmaceutical company
- Roche
- BNF chapter
- Nutrition and blood
- Submission type
- Full
- Publication due date:
- TBC
- SMC meeting date:
- TBC
- Patient group submission deadline:
- 04 August 2026